Find therapies in clinical trials near you – page 2

Study of Trastuzumab Deruxtecan and Rilvegostomig for Patients with Advanced HER2-positive Biliary Tract Cancer

Study of Trastuzumab Deruxtecan and Rilvegostomig for Patients with Advanced HER2-positive Biliary Tract Cancer

Study on Detecting Tumor DNA in Blood for Patients with HR+, HER2 Low Metastatic Breast Cancer Using Trastuzumab Deruxtecan After Standard Therapy

Study on Detecting Tumor DNA in Blood for Patients with HR+, HER2 Low Metastatic Breast Cancer Using Trastuzumab Deruxtecan After Standard Therapy

Study of Trastuzumab Deruxtecan and Drug Combination for Patients with Advanced or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

Study of Trastuzumab Deruxtecan and Drug Combination for Patients with Advanced or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

Study on Imaging and Treatment Prediction for Metastatic Breast Cancer Using Gallium (68Ga) Tezatabep Matraxetan and Trastuzumab Deruxtecan

Study on Imaging and Treatment Prediction for Metastatic Breast Cancer Using Gallium (68Ga) Tezatabep Matraxetan and Trastuzumab Deruxtecan

A Study of Trastuzumab Deruxtecan Treatment for Patients with Early-Stage HER2-Positive or HER2-Low Breast Cancer Who Show Signs of Molecular Relapse

A Study of Trastuzumab Deruxtecan Treatment for Patients with Early-Stage HER2-Positive or HER2-Low Breast Cancer Who Show Signs of Molecular Relapse

Study of Trastuzumab Deruxtecan for Patients with Early Stage HER2-Positive Breast Cancer

Study on zAvatar Test for Treatment Decisions in Relapsed Ovarian Cancer and Metastatic Breast Cancer Using Palbociclib and Drug Combination for Eligible Patients

Study on zAvatar Test for Treatment Decisions in Relapsed Ovarian Cancer and Metastatic Breast Cancer Using Palbociclib and Drug Combination for Eligible Patients

Study on Long-Term Safety of Trastuzumab Deruxtecan for Patients with Advanced HER2-Positive or HER2-Mutated Solid Tumors

Study on Long-Term Safety of Trastuzumab Deruxtecan for Patients with Advanced HER2-Positive or HER2-Mutated Solid Tumors

Study to Determine the Best Dose of Zongertinib with Trastuzumab Deruxtecan or Trastuzumab Emtansine for Patients with Advanced HER2+ Metastatic Cancer

Study to Determine the Best Dose of Zongertinib with Trastuzumab Deruxtecan or Trastuzumab Emtansine for Patients with Advanced HER2+ Metastatic Cancer

Study of AZD9574 and Temozolomide for Patients with Advanced Solid Tumors, Including Breast, Ovarian, Pancreatic, and Prostate Cancers

Study of AZD9574 and Temozolomide for Patients with Advanced Solid Tumors, Including Breast, Ovarian, Pancreatic, and Prostate Cancers

Study on the Effectiveness of Trastuzumab Deruxtecan in Patients with HER2-Positive Oligometastatic Breast Cancer

Study on the Effectiveness of Trastuzumab Deruxtecan in Patients with HER2-Positive Oligometastatic Breast Cancer

Study on Trastuzumab Deruxtecan and Fluorouracil for Patients with HER2-Positive Gastric or Gastroesophageal Cancer with Minimal Residual Disease

Study on Trastuzumab Deruxtecan and Fluorouracil for Patients with HER2-Positive Gastric or Gastroesophageal Cancer with Minimal Residual Disease